According to the official website of the Changzhi municipal government, the goal of this project is to foster substantial progress in the manufacturing of antibody biopharmaceuticals in Shanxi

Havana, Feb 7 (RHC) Officials from Cuba and China have inaugurated the first phase of a Sino-Cuban biopharmaceutical company in Changzhi, which is located in the city's high-tech industrial development zone.

The Cuban ambassador to China, Alberto Blanco, shared on his personal X account that this move reiterates the immense potential for enhancing bilateral collaboration in this area.

The governor of Shanxi Province, Jin Xiangjun, emphasized the significance of ensuring the availability of crucial elements and auxiliary services for this collaborative effort in drug research, development, and commercialization.

According to the official website of the Changzhi municipal government, the goal of this project is to foster substantial progress in the manufacturing of antibody biopharmaceuticals in Shanxi.

The city of Changzhi focuses on developing industries such as electronic information, renewable energy, biomedicine, and high-end equipment manufacturing. It is also working to establish a billion-yuan industrial park and a provincial demonstration zone for transformation and comprehensive reform.

Ambassador Blanco recently confirmed that the relationship between China and Cuba in the field of biotechnology has been progressing for the past two decades.

In an interview with Prensa Latina, Bai Xianhong, the CEO of Biotech Pharmaceuticals Limited (BPL), expressed his admiration for the work of Cuban scientists and experts.

He also referred to BPL as the most significant partnership between the two countries in the biopharmaceutical sector, highlighting the success of the first humanized monoclonal antibody developed by the Asian giant.

Thanks to this partnership, the drug Nimotuzumab has been a successful cancer treatment for over 300,000 patients in China.

Similarly, Bai stated that collaboration with Cuba will persist in the future, with the joint venture enhancing the production capabilities of monoclonal antibodies and establishing state-of-the-art perfusion lines based on mammalian cell culture. (Source: Prensa Latina)